Research progress in plasma concentration monitoring of rivaroxaban
10.12092/j.issn.1009-2501.2023.07.012
- Author:
Qiaoling YU
1
;
Weiwei ZHAI
1
;
Ping LIU
1
;
Huizhen WU
1
;
Qiaoling YU
2
;
Weiwei ZHAI
2
;
Ping LIU
2
;
Bo QIU
2
;
Huizhen WU
2
Author Information
1. Graduate School of Hebei Medical University
2. Departmentof Pharmacy, Hebei General Hospital
- Publication Type:Journal Article
- Keywords:
new oral anticoagulants;
rivaroxaban;
therapy drug monitoring
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2023;28(7):809-817
- CountryChina
- Language:Chinese
-
Abstract:
Rivaroxaban, a novel oral anticoagulant drug, is widely prescribed in clinical practice. Rivaroxaban offers predictable pharmacokinetic and pharmacodynamic properties, a lowprobability of drug-drug and food-drug interactions. Compared with warfarin, rivaroxaban does not require continuous therapeutic monitoring and can be administered in fixed doses.However,in certain emergency clinical situations, such as bleeding, acute stroke, acute kidney injury, prior to urgent surgery and in the suspected accumulation of durg, plasma concentration monitoring of rivaroxaban is necessary and important for patients. Existing studies proved that there were significant individual variability and wide range in the plasma rivaroxaban concentration, which increased the risk of clinical use. Therefore, Data in the degree of rivaroxaban concentration may provide recommendations for the clinical application to promote medication safety and individuality in the future. This article collected the latest literatures and case reports related to research progress of rivaroxaban plasma concentration monitoring, and Summarized influencing factors, monitoring methods, so as to provide a basis for further study on rational use of rivaroxaban in clinical.
